Ipsum Diagnostics has received emergency use authorization from the U.S. Food and Drug Administration (FDA) for its IDx diagnostic test to identify individuals with SARS-CoV-2, the virus that causes the respiratory disease COVID-19.
For the test, SARS-CoV-2 nucleic acid is first extracted, isolated, and purified from nasopharyngeal and oropharnygeal swab samples. Then, the nucleic acid is reverse transcribed into complementary DNA (cDNA), after which clinicians can use an authorized polymerase chain reaction (PCR) tool for amplification and detection.
